Cargando…
Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody
BACKGROUND: Recent studies have reported that similar to other IgG4 autoimmune diseases, such as muscle-specific kinase antibody-associated myasthenia gravis, most anti-neurofascin-155 (anti-NF155) nodopathies respond well to rituximab treatment, regardless of the dosage. However, there are still a...
Autores principales: | Bai, Yunfei, Li, Wei, Yan, Chuanzhu, Hou, Ying, Wang, Qinzhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086195/ https://www.ncbi.nlm.nih.gov/pubmed/37056784 http://dx.doi.org/10.3389/fimmu.2023.1121705 |
Ejemplares similares
-
Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody
por: Hou, Ying, et al.
Publicado: (2022) -
Case report: Autoimmune nodopathy with concurrent serum and CSF IgG4 anti-neurofascin 155 antibodies
por: Wang, Wanyu, et al.
Publicado: (2022) -
Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody
por: Liu, Bingyou, et al.
Publicado: (2023) -
Clinical and diagnostic features of anti‐neurofascin‐155 antibody‐positive neuropathy in Han Chinese
por: Wang, Wenqing, et al.
Publicado: (2022) -
IgG4 Valency Modulates the Pathogenicity of Anti–Neurofascin-155 IgG4 in Autoimmune Nodopathy
por: Jentzer, Alexandre, et al.
Publicado: (2022)